MRI scans generally aren’t very useful in assessing lung function, but Polarean’s 129Xe gas is trying to change that. Polarean Imaging Plc (LON:POLX) is adding a third clinical trial site to the phase III study of its hyperpolarised 129-Xenon (129Xe) gas magnetic resonance imaging (MRI) technology. MRI scans generally aren't much use when assessing lung function, but Polarean has developed a way in which a small amount of inert gas can change that.
Polarean will be exhibiting at the ATS 115th Annual Conference in Dallas, May 19–21, 2019.
Please visit us at booth # 2717 to learn more about Polarean’s latest technical advances in hyperpolarized gas MRI technology and updates on FDA clinical trials. We look forward to meeting you in Dallas.